Developing Drugs for Heart Failure With Reduced Ejection Fraction: What Have We Learned From Clinical Trials?

There remains a large unmet need for new therapies in the treatment of heart failure with reduced ejection fraction (HFrEF). In the early drug development phase, the therapeutic potential of a drug is not yet fully understood and trial endpoints other than mortality are needed to guide drug developm...

Descripción completa

Detalles Bibliográficos
Autores principales: Hinder, Markus, Yi, B. Alexander, Langenickel, Thomas H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Reviews
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5947521/
https://www.ncbi.nlm.nih.gov/pubmed/29315510
http://dx.doi.org/10.1002/cpt.1010

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5947521/
https://www.ncbi.nlm.nih.gov/pubmed/29315510
http://dx.doi.org/10.1002/cpt.1010

Ejemplares similares